press_release_conclusion: A new drug for the muscle-wasting disease Duchenne muscular dystrophy has shown significant benefits in mice, opening the door for clinical trials.
abstract_conclusion: The best compound identified, SMT C1100, demonstrated significant disease modifying effects in DMD models.